Literature DB >> 28661086

Selective Plasma Exchange for the Removal of Pemphigus Autoantibodies, Fibrinogen, and Factor XIII in Pemphigus Vulgaris.

Satoko Miyamoto1, Atsushi Ohkubo1, Hiroshi Seshima1, Shigeto Komori1, Motoki Yamamoto1, Takuma Maeda1, Ayako Itagaki1, Hiroko Yamamoto1, Kohei Nojima2, Soichiro Iimori3, Shotaro Naito3, Naoki Kurashima1, Eisei Sohara3, Tatemitsu Rai3, Shinichi Uchida3, Tomokazu Okado3.   

Abstract

Pemphigus vulgaris is a serious autoimmune skin disorder associated with desmoglein 1 and 3. Selective plasma exchange (SePE) for pemphigus vulgaris remains unknown. We investigated the removal characteristics of pemphigus autoantibodies, immunoglobulins, and fibrinogen in three cases. When the mean processed volume for SePE was 1.2 plasma volumes, the mean percent reduction was 50.7% for desmoglein 1, 48.9% for desmoglein 3, 50.3% for IgG, 29.8% for IgA, 1.9% for IgM, and 17.6% for fibrinogen. In one case, the percent reduction after four sessions of SePE within eight days was 87.0% for desmoglein 1, 85.1% for desmoglein 3, 76.6% for IgG, 53.5% for IgA, 7.9% for IgM, 41.6% for fibrinogen, and 31.4% for factor XIII. SePE can effectively remove pemphigus autoantibodies and retain coagulation factors, e.g. factor XIII and fibrinogen. In severe cases, SePE can be useful and safe for induction therapy.
© 2017 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.

Entities:  

Keywords:  Desmoglein; Factor XIII; Fibrinogen; Pemphigus vulgaris; Selective plasma exchange

Mesh:

Substances:

Year:  2017        PMID: 28661086     DOI: 10.1111/1744-9987.12555

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  1 in total

1.  Experience of therapeutic plasma exchange in rheumatic diseases: Albumin may be a suitable substitute for plasma.

Authors:  Zhiqian Bai; Yu Chen; Lingli Dong
Journal:  Arch Rheumatol       Date:  2021-03-16       Impact factor: 1.472

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.